Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT).
September 09, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Arcturus Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests a positive sentiment towards Arcturus Therapeutics, likely leading to a short-term increase in stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100